Improved outcomes associated with fidaxomicin compared with vancomycin suggest benefits from its greater use in Medicare patients, although uptake remains low despite its recommended use. The recently ...

Research found fecal microbiota transplantation (FMT) to be an optimal cost-effective treatment strategy for first and subsequent recurrent Clostridioides difficile infection (CDI), challenging ...

To assess the efficacy of the policy, the researchers compared 141 CDI episodes in the pre-implementation group with 283 post-implementation episodes. They found the overall treatment concordance to ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The American ...

Please provide your email address to receive an email when new articles are posted on . Fecal microbiota-based therapies are becoming more prevalent in the management of Clostridioides difficile ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

Please provide your email address to receive an email when new articles are posted on . New guidelines issued in 2021 stated a preference for fidaxomicin as first-line treatment for Clostridioides ...

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...

Clostridium bacteria, computer illustration. Clostridia are spore-forming bacteria that include several human pathogenic species, C. difficile, C. tetani, C. botulinum, C. perfringens, and others. C.

Thirty-day all-cause mortality among patients with severe Clostridium difficile infection (CDI) was significantly lower when vancomycin was used as first-line therapy compared with metronidazole, ...